A community for people who want to remain as healthy as possible as we age.

AstraZeneca's Tagrisso to cost $12,750 for a month's supply

(Reuters) AstraZeneca's new lung cancer pill Tagrisso, which won early U.S. approval on Friday, will cost $12,750 for a month's supply.
A company spokeswoman said on Tuesday the wholesale acquisition cost was comparable to other targeted oral lung cancer therapies, such as Pfizer's Xalkori and Novartis' Zykadia.
AstraZeneca has previously said it believes Tagrisso could generate peak sales of $3 billion a year, making it a key product in the group's growing oncology portfolio.
[Click the title, above, to post a comment.]

0 comments:

Post a Comment

Please do not give advice. We can best help each other by telling what works for us, not what we think someone else should do.